Imperial College London
Portrait Picture

ProfessorNicholaCooper

Faculty of Medicine, Department of Immunology and Inflammation

Professor of Immune Haematology
 
 
 
//

Contact

 

n.cooper

 
 
//

Assistant

 

Miss Mandy Sale +44 (0)20 3313 4017

 
//

Location

 

4S10CCommonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Pell:2018:10.1136/bmjopen-2018-024427,
author = {Pell, J and Greenwood, R and Ingram, J and Wale, K and Thomas, I and Kandiyali, R and Mumford, A and Dick, A and Bagot, C and Cooper, N and Hill, Q and Bradbury, CA},
doi = {10.1136/bmjopen-2018-024427},
journal = {BMJ Open},
pages = {e024427--e024427},
title = {Trial protocol: a multicentre randomised trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The FLIGHT trial},
url = {http://dx.doi.org/10.1136/bmjopen-2018-024427},
volume = {8},
year = {2018}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - <jats:sec><jats:title>Introduction</jats:title><jats:p>Immune thrombocytopenia (ITP) is an autoimmune condition that may cause thrombocytopenia-related bleeding. Current first-line ITP treatment is with high-dose corticosteroids but frequent side effects, heterogeneous responses and high relapse rates are significant problems with only 20% remaining in sustained remission with this approach. Mycophenolate mofetil (MMF) is often used as the next treatment with efficacy in 50%–80% of patients and good tolerability but can take up to 2 months to work.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>To test the hypothesis that MMF combined with corticosteroid is a more effective first-line treatment for immune thrombocytopenia (ITP) than current standard of corticosteroid alone.</jats:p></jats:sec><jats:sec><jats:title>Methods and analysis</jats:title><jats:sec><jats:title>Design</jats:title><jats:p>Multicentre, UK-based, open-label, randomised controlled trial.</jats:p></jats:sec></jats:sec><jats:sec><jats:title>Setting</jats:title><jats:p>Haematology departments in secondary care.</jats:p></jats:sec><jats:sec><jats:title>Participants</jats:title><jats:p>We plan to recruit 120 patients >16 years old with a diagnosis of ITP and a platelet count <30x10<jats:sup>9</jats:sup>/L who require first-line treatment. Patients will be followed up for a minimum of 12 months following randomisation.</jats:p></jats:sec><jats:sec><jats:title>Primary outcome</jats:title><jats:p>Time from randomisation to treatment failure defined as platelets <30x10<jats:sup>9</jats:sup>/L and a need for second-line treatment.</jats:p></jats:sec><jats:sec><jats:title>Secondary outc
AU  - Pell,J
AU  - Greenwood,R
AU  - Ingram,J
AU  - Wale,K
AU  - Thomas,I
AU  - Kandiyali,R
AU  - Mumford,A
AU  - Dick,A
AU  - Bagot,C
AU  - Cooper,N
AU  - Hill,Q
AU  - Bradbury,CA
DO  - 10.1136/bmjopen-2018-024427
EP  - 024427
PY  - 2018///
SN  - 2044-6055
SP  - 024427
TI  - Trial protocol: a multicentre randomised trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The FLIGHT trial
T2  - BMJ Open
UR  - http://dx.doi.org/10.1136/bmjopen-2018-024427
VL  - 8
ER  -
Download